We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Multiple Genetic Changes Linked to Increased Pancreatic Cancer Risk

By LabMedica International staff writers
Posted on 06 Jul 2015
A genome-wide association study, believed to be the largest of its kind, has uncovered four regions in the human genome where changes may increase the risk of pancreatic cancer. More...


Patients with pancreatic cancer are also often diagnosed at late stages of the disease, making it tougher to identify genetic risk factors, even though it is the fourth leading cause of cancer death in the USA, but it is not as commonly diagnosed as other cancers, such as breast or colorectal cancer.

A large team of international scientists led by those associated with Johns Hopkins School of Public Health (Baltimore, MD, USA) performed a genome-wide association study on 9,925 pancreatic cancer cases and 11,569 controls, including 4,164 newly genotyped cases and 3,792 controls in nine studies from North America, Central Europe and Australia. Genotyping results were inspected for quality by assessing the missing call rate, allelic imbalance, heterozygosity, discordance in reported versus genotyped sex, relatedness, ancestry, and chromosomal anomalies.

The team identified genetic variants are located at several positions on human chromosomes, including position 17q25.1, which may increase cancer risk by 38% for each copy that is present in the genome; position 7p13, which may increase the risk by 12%; and position 3q29, which may increase the risk by 16%. Position 2p13.3, another genetic region pinpointed in the study, was previously linked with pancreatic cancer risk in a study of Han Chinese people, and the current study provides more definitive evidence of different genetic changes in that region believed to increase pancreatic cancer risk by 14%.

Alison Klein, PhD, an associate professor of oncology and co-author of the study, said, “These variants are common in the population, and most individuals who have these variants will never develop pancreatic cancer in their lifetime. However, identifying and understanding these changes can lead to a better understanding of why some people develop pancreatic cancer. If we combine this information with data on other pancreatic cancer risk factors, we may be able to identify and one day screen high-risk groups. If we can identify high-risk populations, we can eventually get to the point where we can detect pancreatic cancer early, when the disease is most treatable, and save lives.” The study was published on June 22, 2015, in the journal Nature Genetics.

Related Links:

Johns Hopkins School of Public Health 



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.